Huiyu Pharmaceutical (688553.SH): Concentrated solution of sodium valproate for injection, etc. obtained overseas marketing approval

Zhitongcaijing · 22h ago

Zhitong Finance App News, Huiyu Pharmaceuticals (688553.SH) announced that its subsidiary Seacross Pharmaceuticals Ltd., recently received marketing approval for the company's products sodium valproate injectable concentrated solution, fluvizil injection, cyclophosphamide for injection, levetiracetam concentrated solution and sodium thiosulfate injection, which were approved and issued by the Kosovo Medicines and Health Products Administration respectively.

According to reports, concentrated solution of sodium valproate for injection is an anticonvulsant. In adults and children, it is used to replace the oral dosage form when the oral dosage form cannot be taken for the time being. It is mainly used to treat generalized seizures, which manifest as syncope attacks, muscle twitching seizures, tonic-clonic seizures, and focal and secondary generalized seizures.

Flunavistin injection is an anticancer drug used for locally advanced or metastatic breast cancer that recurs after or during treatment with antiestrogen-assisted treatment, or progressed during anti-estrogen therapy (including natural menopause and artificial menopause) with positive estrogen receptors; combination treatment with abecilil is suitable for locally advanced or metastatic breast cancer that is hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, and is used in patients who have progressed after previous endocrine therapy.